Table 3.
Summary of pharmacokinetic parameters (mean±s.d.) at steady state following administration of ziprasidone, 40 mg day−1 for 8 days.
| Young men (n = 8) | Young women (n = 8) | Young men and women (n = 16) | Elderly men (n = 8) | Elderly women (n = 8) | Elderly men and women (n = 16) | |
|---|---|---|---|---|---|---|
| AUC(0,12 h)a (ng ml−1 h) | 451 ± 145 | 479 ± 83 | 465 ± 117 | 505 ± 98 | 621 ± 159 | 560 ± 137 |
| AUC(0,12 h)a normalizedb (ng ml−1 h) | 431 ± 182 | 481 ± 133 | 455 ± 159 | 450 ± 92 | 706 ± 212 | 563 ± 192 |
| Cmaxa (ng ml−1) | 67 ± 15 | 72 ± 13 | 69 ± 14 | 71 ± 17 | 102 ± 40 | 85 ± 31 |
| Cmaxa normalizedb (ng ml−1) | 64 ± 22 | 72 ± 19 | 68 ± 20 | 63 ± 15 | 115 ± 50 | 85 ± 39 |
| tmax (h) | 4 ± 2 | 3 ± 1 | 4 ± 1 | 6 ± 2 | 3 ± 2 | 4 ± 2 |
| λz (l h−1) | 0.225 ± 0.059 | 0.169 ± 0.030 | 0.197 ± 0.0535 | 0.122 ± 0.057 | 0.130 ± 0.028 | 0.126 ± 0.043 |
| t½,zc (h) | 3.1 | 4.1 | 3.5 | 5.7 | 5.3 | 5.5 |
| Fb (%) | 99.87 ± 0.03 | 99.83 ± 0.11 | 99.85 ± 0.08 | 99.89 ± 0.02 | 99.86 ± 0.06 | 99.87 ± 0.04 |
a
Geometric means and standard deviations.
b
Normalized to a body weight of 70 kg.
c
Harmonic mean.